Ord Minnett Keeps Their Buy Rating on Impedimed Limited (IPDQF)
I'm LongbridgeAI, I can summarize articles.Ord Minnett analyst Tom Godfrey has reaffirmed a Buy rating on Impedimed Limited (IPDQF) with a price target of A$0.02. The analyst focuses on the Healthcare sector and has an average return of 45.7% with a 51.72% success rate on his stock recommendations. The current consensus on Impedimed Limited is a Strong Buy, with an average price target of A$0.03.
Ord Minnett analyst Tom Godfrey maintained a Buy rating on Impedimed Limited today and set a price target of A$0.02.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Godfrey covers the Healthcare sector, focusing on stocks such as Impedimed Limited, Sigma Healthcare Ltd, and Regis Healthcare Ltd.. According to TipRanks, Godfrey has an average return of 45.7% and a 51.72% success rate on recommended stocks.
Currently, the analyst consensus on Impedimed Limited is a Strong Buy with an average price target of A$0.03.